Investigation on the in vitro effects of resveratrol on peripheral blood mononuclear cells harvested from healthy and atopic dogs

Canine atopic dermatitis (AD) is a common skin disease. Many therapeutic options are available to decrease inflammation and ameliorate pruritus. However, those treatments are associated with side effects, a long lag phase for efficacy, or high expense. Natural plant extracts have been identified as possible, safer alternatives to traditional anti-inflammatory and antipruritic drugs. Resveratrol has been revisited as a new, possible alternative for its numerous beneficial properties. The purpose of this study was to evaluate the in vitro effects of resveratrol on peripheral blood mononuclear cells (PBMC) harvested from healthy and atopic privately-owned dogs.

The PBMC harvested from nine healthy and 11 atopic dogs were isolated and exposed to four concentrations (1.5-9 μg/mL) of resveratrol both with or without phytohemagglutinin stimulation. After 24 h cytotoxicity, host defense peptides (HDPs), as well as oxidative stress (catalase and superoxide dismutase), and pro-inflammatory cytokines were assessed. Cytotoxicity was not observed in either group under any experimental conditions. An increase in catalase was only seen in healthy PBMC after exposure to low concentrations of resveratrol (p ≤ 0.03). Resveratrol did not show any effect on canine HDPs. Compared to baseline, there was a significant reduction in monocyte chemotactic protein-1 and interleukin-6 after exposure to 9 μg/mL of resveratrol in unstimulated healthy (p = 0.029) and stimulated atopic (p = 0.0075) PBMC. In conclusion, these data confirm the overall lack of cytotoxicity of resveratrol on healthy and atopic PBMC at the tested concentrations. However, at the concentrations tested, there was only a minimal effect of resveratrol on the secretion of HDPs and pro-inflammatory cytokines.